Alembic Reports Strong Q3 FY24-25 Results with Significant Year-on-Year Growth

Alembic, a small-cap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results, declared on February 7, 2025, indicate a very positive performance for Q3 FY24-25, with the stock's evaluation remaining unchanged over the past three months.
The financial data reveals that Alembic achieved a Profit Before Tax less Other Income (PBT) of Rs 23.02 crore, reflecting a significant year-on-year growth of 166.44%. This marks the highest PBT recorded in the last five quarters, showcasing a strong near-term trend. Additionally, net sales reached Rs 57.92 crore, also the highest in the past five quarters, with a year-on-year growth of 47.30%. This consistent upward trajectory in sales further underscores the company's robust performance.

Moreover, the Profit After Tax (PAT) for the half-year stood at Rs 186.41 crore, indicating a year-on-year growth of 22.57%. Operating Profit (PBDIT) also reached a peak of Rs 26.40 crore in the last five quarters, reinforcing the positive trends observed in the company's financial metrics.

For those interested in further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.